title: Prospective randomized study of antibiotic prophylaxis for nonlaparotomy surgery in benign conditions.
abstract: BACKGROUND
  Although postoperative infections continue to be a major problem in gynecologic surgery, there is still no consensus on the efficacy of antibiotic prophylaxis.
  
  
  METHODS
  This prospective randomized trial was conducted to investigate the prevention of major operating site infections after nonlaparotomy surgery, with treatment regimens as follows: the first group of patients received 2 g of intravenous cefotiam dihydrochloride (CTM) on the induction of anesthesia, while the second group received 100 mg of oral cefpodoxime proxetil (CPDX- PR) twice daily, from day 0 to day 2.
  
  
  RESULTS
  Nineteen of the 207 patients enrolled developed postoperative infections diagnosed by our simple criteria for postoperative infection. The frequency of febrile morbidity was not significantly less in patients who received CTM (9 cases; 8.6%) as compared with those in the CPDX-PR group (10 cases; 9.8%) (p = 0.56).
  
  
  CONCLUSIONS
  The administration of oral CPDX-PR (100 mg, twice daily, for 3 days) appears to be a safe, cost-saving, convenient prophylaxis which reduces overall expense.
authors.affiliation: Department of Gynecology and Obstetrics, Asahikawa Medical College, Asahikawa, Hokkaidou, Japan. gynhayas@asahikawa-med.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Hayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Yaginuma
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: A
authors.initials: A
authors.lastname: Morizaki
authors.forename: T
authors.initials: T
authors.lastname: Ishiya
authors.forename: Y
authors.initials: Y
authors.lastname: Katou
authors.forename: M
authors.initials: M
authors.lastname: Ishikawa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019072:Antibiotic Prophylaxis; D015310:Cefotiam / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007275:Injections, Intravenous; D010535:Laparoscopy; D008875:Middle Aged; D011183:Postoperative Complications / Q000382:microbiology / Q000517:prevention & control*; D011446:Prospective Studies; D013530:Surgical Wound Infection / Q000382:microbiology / Q000517:prevention & control; D000097623:Cefpodoxime
chemical_list: D015310:Cefotiam; D015296:Ceftizoxime; D002511:Cephalosporins; D000097623:Cefpodoxime